In Week of Mar 28, 2026, J B Chemicals & Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +24.7% relative strength. Fundamentals: Average. On a 7-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Complete debt repayment leading to surplus cash deployment boosting other income
“Narayan Saraf: "since we have repaid all our debts, we had some opening debts in last year and now we have repaid all our debts and we have a surplus cash which we are investing as per our treasury policy and that's resulting into higher treasury income."”
What: Strong performance in South Africa, Russia and export branded business continuing
Impact: +₹50 Cr revenue
“Management: "Equally in the international market we have bounced back in quarter three and that momentum will continue in quarter four backed up by our subsidiaries doing better, South Africa, Russia as well as international Branded business is also showed a bit for the quarter"”
What: Focus on higher-margin chronic therapy products driving margin expansion
“Management: "Gross margins during the quarter three rose by 200bps to 69.1% as compared to 67.1% last year. This is on the backup of attractive product mix, price improvement realized and stable raw material cost."”
Earnings deceleration risks from management commentary
Trigger: March quarter dynamics
Impact: -100 bps margin impact
Management view: Jason D'souza: "March generally is a soft month for all Indian pharmaceutical companies for domestic market situation because of the inventory closing from the distributor's end. So that quarterly run rate can be impacted because of natural March phenomena."
Monitor: Domestic growth rate in Q4
Trigger: Increased competition
Impact: -200 bps margin impact
Management view: Management focus on "driving profitability" and "sustained investments" to protect margins indicates competitive pressures exist
Monitor: Gross margin trajectory
Key quotes from recent conference calls
“Gross margins during the quarter three rose by 200bps to 69.1% as compared to 67.1% last year. This is on the backup of attractive product mix, price improvement realized and stable raw material cost. — Unidentified Speaker”
“since we have repaid all our debts, we had some opening debts in last year and now we have repaid all our debts and we have a surplus cash which we are investing as per our treasury policy and that's resulting into higher treasury income. — Narayan Saraf”
“Equally in the international market we have bounced back in quarter three and that momentum will continue in quarter four backed up by our subsidiaries doing better, South Africa, Russia as well as international Branded business is also showed a bit for the quarter and we should end the year for our international business at high single digit growth — Unidentified Speaker”
“quarter four as what we have earlier said India business should grow two to 300 days better than the market an international business as we have good order book we should show the same performance as what we have demonstrated for quarter three which by the end of the year should go at high single digit. — Unidentified Speaker”
Forward-looking targets from management for FY26
Revenue Growth Target
7.5%
Implied PAT Growth
15%
OPM Guidance
28.5%
Key Milestones
• International business high single-digit growth
• Domestic business outperforming market by 2-3%
• EBITDA margins close to 28-29%
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +11% | +17% | Stable |
| PAT (Net Profit) | +22% | +20% | Stable |
| OPM | 28.0% | +200 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
J B Chemicals & Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
J B Chemicals & Pharmaceuticals Ltd's profit is growing with an stable trend.
J B Chemicals & Pharmaceuticals Ltd's revenue growth trend is stable.
J B Chemicals & Pharmaceuticals Ltd's operating margin is expanding.
J B Chemicals & Pharmaceuticals Ltd's long-term compounding rates
J B Chemicals & Pharmaceuticals Ltd's earnings growth is stable with weakening on a sequential basis.
J B Chemicals & Pharmaceuticals Ltd's trailing twelve month (TTM) performance
J B Chemicals & Pharmaceuticals Ltd appears slightly undervalued based on our fair value analysis.
J B Chemicals & Pharmaceuticals Ltd's current PE ratio is 43.8x.
J B Chemicals & Pharmaceuticals Ltd's current PE is 43.8x.
J B Chemicals & Pharmaceuticals Ltd's price-to-book ratio is 8.5x.
J B Chemicals & Pharmaceuticals Ltd is rated Average with a fundamental score of 53.97/100. This score is calculated from objective financial metrics
J B Chemicals & Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
J B Chemicals & Pharmaceuticals Ltd's return ratios over recent years
J B Chemicals & Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
J B Chemicals & Pharmaceuticals Ltd's current dividend yield is 0.75%.
J B Chemicals & Pharmaceuticals Ltd's shareholding pattern (Jan 2026)
J B Chemicals & Pharmaceuticals Ltd's promoter holding has increased recently.
J B Chemicals & Pharmaceuticals Ltd has been outperforming Nifty 500 for 7 consecutive weeks, indicating building momentum.
J B Chemicals & Pharmaceuticals Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
J B Chemicals & Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
J B Chemicals & Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26, J B Chemicals & Pharmaceuticals Ltd's management highlighted
J B Chemicals & Pharmaceuticals Ltd's management has provided the following forward guidance for FY26
Based on quantitative research signals, here is why J B Chemicals & Pharmaceuticals Ltd may be worth studying
J B Chemicals & Pharmaceuticals Ltd investment thesis summary:
J B Chemicals & Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
